Furthermore, a bispecific antibody (GSK3178022) to LRP6 that is capable of blocking stimulation by a range of WNT and R-spondin (RSPO) ligands in vitro potently delayed tumor growth in a patient-derived RSPO fusion model of CRC (Table 2) [70]. This evidence concerns the gene LRP6 and neoplasm.